Episode #15
The Missing Middle: Life Sciences Real Estate's Smallest Tenants
Episode 13: The Missing Middle: Life Sciences Real Estate's Smallest Tenants Episode description States love to recruit the marquee win — the mega-plant, the ribbon cutting. But the company that actually seeds a life sciences cluster ten years from now rarely looks like that. It's small, pre-revenue, and scientifically brilliant people who have no idea how to read a lease. This episode follows that gap — the "missing middle" of life sciences real estate — through three vantage points: a brokerage building a resource to keep early-stage biotech tenants from getting stuck in bad leases, a university tech-transfer office building the infrastructure to catch companies before they fail, and a 100-year-old pharmaceutical company that's already on the other side of it, breaking ground on a $2 billion biologics facility built to last generations. Guests David Klein , Managing Partner, Lee & Associates (San Francisco) Elijah Hodges , Life Sciences Team, Lee & Associates Kathy Nugent , Director, Institute for Innovation and Entrepreneurship, University of Alabama at Birmingham (UAB) Ray Watts , President, University of Alabama at Birmingham Philippe Mantelet , Head of Global Engineering, Sites and Facilities, UCB In this episode Segment 1 — The lease nobody prepared them for. David Klein and Elijah Hodges of Lee & Associates built LabSpace Directory, a free resource for early-stage biotech tenants navigating their first lab lease. Klein describes the two failure modes that wreck young life sciences companies: under-programming space and getting trapped renegotiating with a landlord who holds all the leverage, or over-leasing and getting saddled with dark space the company can't afford. Hodges explains why founders — deep experts in their own science — routinely skip the real estate, architecture, and space-planning professionals who could keep them out of trouble. Segment 2 — Building the infrastructure to catch them. At UAB, Kathy Nugent and President Ray Watts describe an institution built almost entirely around life sciences: 93% of UAB's research funding comes from NIH, and 95% of the companies it has spun out in the last five years are biotech. Nugent details UAB's approach to the gap between discovery and company — recruiting CEOs who don't relocate to Birmingham but keep the company's footprint there, and building Station 41, an 11,000-square-foot wet lab incubator (expanding to 30,000) a block from campus. Alabama's Innovate Alabama tax credit program funnels contract research funding — up to $400,000–$500,000 per company — to help early-stage tenants there access preclinical services. Segment 3 — The other side of the gap. Philippe Mentolea of UCB, the Belgian family-owned pharmaceutical company, discusses the $2 billion biologics manufacturing facility UCB is building in Gwinnett County, Georgia — a project meant to anchor its U.S. manufacturing supply chain for decades. Mentolea explains what won Georgia the project (a 30-year relationship, site readiness, and shared long-term vision), why none of the competing sites "failed" so much as one edged ahead on fit, and the advice he'd give other site selectors: don't chase short-term incentives on a project built to last a generation. Notable lines "It's scientists who are brilliant at biology and chemistry that have no idea how to read a lease." — David Klein "I don't know. You tell me." / "I can't tell you. You have to tell me." — Klein, on CEOs who haven't programmed their space needs "I hate using the word valley of death... but it's pretty steep right now." — Kathy Nugent "Failing or failure is not an option, and there is no blocking point." — Philippe Mentolea Credits Hosted by Andy Greiner, editor, Area Development magazine. A production of Area Development / Halcyon Business Publications. Mentioned in this episode: This episode is sponsored by TNECD
